Back to results
US 2019/0240221 A1Published application
Composition comprising combination of trh analog with arundic acid, and pharmaceutically acceptable salt of arundic acid
AssigneeBrivention Pharmaceutical (Shanghai) Inc.
InventorsMichio YAMAMURA, Narito TATEISHI
Life of this patent
Estimating the term…
Abstract
An object of this invention is to provide a composition for preventing and/or treating neurodegenerative diseases and cerebral infarction, and a composition for ameliorating learning disorders. Provided is a composition comprising a combination of a TRH analog and arundic acid.
Claims11
-8. (canceled)
A compound represented by Formula (II) or a solvate thereof:
- wherein X2+ is a divalent cation.
A method for producing a compound represented by Formula (II):
- wherein X2+ is a divalent cation,
- the method comprising allowing a divalent cation to act on arundic acid in at least one solvent selected from the group consisting of methyl tert-butyl ether, acetonitrile, and dichloromethane.
A composition comprising a combination of
- (A) at least one member selected from the group consisting of compounds represented by Formula (I), pharmaceutically acceptable salts thereof, and hydrates thereof, and
- (B) at least one member selected from the group consisting of arundic acid, pharmaceutically acceptable salts thereof, and pharmaceutically acceptable solvates thereof
- wherein R is hydrogen or C1-6 alkyl.
Dependencies are inferred from the claim text.